-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
PerkinElmer, Inc. (NYSE:PKI) Stock Holdings Cut by Steigerwald Gordon & Koch Inc.
PerkinElmer, Inc. (NYSE:PKI) Stock Holdings Cut by Steigerwald Gordon & Koch Inc.
Steigerwald Gordon & Koch Inc. decreased its holdings in shares of PerkinElmer, Inc. (NYSE:PKI – Get Rating) by 0.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 110,240 shares of the medical research company's stock after selling 142 shares during the quarter. PerkinElmer comprises about 2.7% of Steigerwald Gordon & Koch Inc.'s investment portfolio, making the stock its 8th largest position. Steigerwald Gordon & Koch Inc.'s holdings in PerkinElmer were worth $15,678,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the business. Allworth Financial LP increased its position in PerkinElmer by 14,100.0% during the first quarter. Allworth Financial LP now owns 284 shares of the medical research company's stock valued at $50,000 after acquiring an additional 282 shares during the last quarter. Covestor Ltd increased its position in PerkinElmer by 25.1% during the first quarter. Covestor Ltd now owns 359 shares of the medical research company's stock valued at $63,000 after acquiring an additional 72 shares during the last quarter. MV Capital Management Inc. increased its position in PerkinElmer by 1,085.1% during the first quarter. MV Capital Management Inc. now owns 557 shares of the medical research company's stock valued at $97,000 after acquiring an additional 510 shares during the last quarter. Ellevest Inc. increased its position in PerkinElmer by 35.3% during the first quarter. Ellevest Inc. now owns 716 shares of the medical research company's stock valued at $125,000 after acquiring an additional 187 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd increased its position in PerkinElmer by 128.4% during the first quarter. Harvest Fund Management Co. Ltd now owns 765 shares of the medical research company's stock valued at $133,000 after acquiring an additional 430 shares during the last quarter. Hedge funds and other institutional investors own 77.06% of the company's stock.
Get PerkinElmer alerts:Insider Transactions at PerkinElmer
In other news, insider Andrew Okun sold 3,173 shares of the firm's stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $165.42, for a total transaction of $524,877.66. Following the sale, the insider now owns 6,391 shares of the company's stock, valued at approximately $1,057,199.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Andrew Okun sold 3,173 shares of PerkinElmer stock in a transaction on Monday, August 1st. The shares were sold at an average price of $165.42, for a total value of $524,877.66. Following the sale, the insider now owns 6,391 shares of the company's stock, valued at approximately $1,057,199.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Daniel R. Tereau sold 5,700 shares of PerkinElmer stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $145.14, for a total transaction of $827,298.00. Following the completion of the sale, the insider now directly owns 13,380 shares in the company, valued at approximately $1,941,973.20. The disclosure for this sale can be found here. Insiders have sold 13,898 shares of company stock valued at $2,083,263 in the last 90 days. 0.52% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
PKI has been the topic of a number of analyst reports. Stifel Nicolaus cut shares of PerkinElmer from a "buy" rating to a "hold" rating and cut their price objective for the company from $190.00 to $170.00 in a research report on Thursday, August 18th. Credit Suisse Group assumed coverage on shares of PerkinElmer in a report on Wednesday, August 24th. They issued a "neutral" rating and a $175.00 price target on the stock. Barclays cut their price target on shares of PerkinElmer from $149.00 to $140.00 and set an "underweight" rating on the stock in a report on Monday, September 12th. UBS Group assumed coverage on shares of PerkinElmer in a report on Wednesday, July 20th. They issued a "buy" rating and a $160.00 price target on the stock. Finally, Bank of America lowered shares of PerkinElmer from a "buy" rating to a "neutral" rating and set a $178.00 price objective for the company. in a research note on Tuesday, August 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $162.50.PerkinElmer Stock Down 1.4 %
Shares of PKI stock traded down $1.81 during mid-day trading on Thursday, hitting $124.14. 10,220 shares of the stock traded hands, compared to its average volume of 672,207. The stock has a market cap of $15.67 billion, a P/E ratio of 23.59, a P/E/G ratio of 0.35 and a beta of 1.14. The stock's fifty day moving average is $143.28 and its two-hundred day moving average is $150.73. PerkinElmer, Inc. has a 52-week low of $125.52 and a 52-week high of $203.16. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.02 and a quick ratio of 1.42.
PerkinElmer (NYSE:PKI – Get Rating) last released its quarterly earnings results on Monday, August 1st. The medical research company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.01 by $0.31. The business had revenue of $1.23 billion during the quarter, compared to analyst estimates of $1.20 billion. PerkinElmer had a net margin of 13.21% and a return on equity of 16.68%. The company's quarterly revenue was up .1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.83 earnings per share. Equities analysts predict that PerkinElmer, Inc. will post 7.83 EPS for the current year.
PerkinElmer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.23%. PerkinElmer's payout ratio is 5.24%.
PerkinElmer Profile
(Get Rating)
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
See Also
- Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI – Get Rating).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.
Steigerwald Gordon&Koch Inc.在向美國證券交易委員會(Securities&Exchange Commission)提交的最新披露中稱,該公司第二季度減持了PerkinElmer,Inc.(紐約證券交易所代碼:PKI-GET評級)的股票0.1%。該機構投資者在本季度出售了142股後,持有這家醫療研究公司110,240股股票。PerkinElmer在S的投資組合中所佔比例約為2.7%,這使該股成為其第八大投資組合。截至最近一個季度末,S持有的PerkinElmer價值15,678,000美元。
其他一些對沖基金最近也買入和賣出了該公司的股票。Allworth Financial LP在第一季度將其在PerkinElmer的頭寸增加了14,100.0%。Allworth Financial LP現在擁有284股這家醫療研究公司的股票,價值5萬美元,在上個季度又購買了282股。Covestor Ltd在第一季度將其在PerkinElmer的頭寸增加了25.1%。Covestor Ltd現在擁有這家醫療研究公司359股股票,價值6.3萬美元,此前在上個季度又購買了72股。MV Capital Management Inc.在第一季度將其在PerkinElmer的頭寸增加了1085.1%。MV Capital Management Inc.現在持有這家醫療研究公司557股股票,價值97,000美元,此前該公司在上個季度增持了510股股票。Ellevest Inc.在第一季度將其在PerkinElmer的頭寸增加了35.3%。Ellevest Inc.現在持有這家醫療研究公司716股股票,價值12.5萬美元,該公司在上個季度增持了187股。最後,嘉實基金管理有限公司在第一季度將其在PerkinElmer的頭寸增加了128.4%。嘉實基金管理有限公司在上個季度增持了430股後,現在持有這家醫學研究公司765股股票,價值13.3萬美元。對沖基金和其他機構投資者持有該公司77.06%的股份。
到達PerkinElmer警報:PerkinElmer的內幕交易
在其他新聞方面,內部人士安德魯·奧肯在8月1日星期一的一筆交易中出售了3173股該公司的股票。這些股票以165.42美元的平均價格出售,總成交金額為524,877.66美元。出售後,這位內部人士現在擁有該公司6,391股股票,價值約1,057,199.22美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可通過美國證券交易委員會網站。在相關新聞中,內部人士安德魯·奧肯在8月1日(星期一)的一筆交易中出售了3173股PerkinElmer股票。這些股票的平均價格為165.42美元,總價值為524,877.66美元。出售後,這位內部人士現在擁有該公司6,391股股票,價值約1,057,199.22美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可通過此超鏈接。此外,內部人士Daniel·R·特羅在7月22日(星期五)的一次交易中出售了5,700股PerkinElmer股票。這些股票以145.14美元的平均價格出售,總成交金額為827,298.00美元。出售完成後,該內部人士現在直接擁有該公司13,380股,價值約1,941,973.20美元。關於這次銷售的披露可以找到這裡。在過去的90天裡,內部人士已經出售了13,898股公司股票,價值2,083,263美元。公司內部人士目前持有該公司0.52%的股份。
華爾街分析師預測經濟增長
公鑰基礎設施已經成為許多分析師報告的主題。Stifel Nicolaus在8月18日週四發佈的一份研究報告中,將PerkinElmer的股票評級從“買入”下調至“持有”,並將該公司的目標價從190.00美元下調至170.00美元。瑞士信貸集團在8月24日星期三的一份報告中對PerkinElmer的股票進行了報道。他們對該股給予了“中性”評級和175.00美元的目標價。巴克萊將PerkinElmer的股票目標價從149.00美元下調至140.00美元,並在9月12日週一的一份報告中將該股的評級定為“減持”。瑞銀集團在7月20日星期三的一份報告中對PerkinElmer的股票進行了報道。他們對該股給予了“買入”評級和160.00美元的目標價。最後,美國銀行將PerkinElmer的股票評級從“買入”下調至“中性”,並為該公司設定了178.00美元的目標價。在8月2日星期二的一份研究報告中。一名投資分析師對該股的評級為賣出,五名分析師給出了持有評級,四名分析師給出了該公司股票的買入評級。根據MarketBeat的數據,該公司目前的平均評級為持有,共識目標價為162.50美元。PerkinElmer股價下跌1.4%
週四午盤,PKI股價下跌1.81美元,至124.14美元。該股有10,220股易手,而其平均成交量為672,207股。該股市值156.7億美元,本益比23.59倍,本益比0.35倍,貝塔係數1.14。該股的50日移動均線切入位為143.28美元,200日移動均線切入位為150.73美元。PerkinElmer,Inc.的52周低點為125.52美元,52周高位為203.16美元。該公司的債務權益比為0.63,流動比率為2.02,速動比率為1.42。
PerkinElmer(紐約證券交易所代碼:PKI-GET Rating)最近一次發佈季度收益報告是在8月1日星期一。這家醫療研究公司公佈本季度每股收益為2.32美元,比普遍預期的2.01美元高出0.31美元。該業務本季度營收為12.3億美元,而分析師預期為12.億美元。PerkinElmer的淨利潤率為13.21%,股本回報率為16.68%。該公司季度營收同比增長1.1%。去年同期,該公司公佈的每股收益為2.83美元。股票分析師預測,PerkinElmer,Inc.本年度每股收益將達到7.83美元。
PerkinElmer宣佈分紅
該公司最近還披露了季度股息,將於11月11日(星期五)支付。10月21日(星期五)登記在冊的股東將獲得每股0.07美元的股息。本次股息除息日期為10月20日(星期四)。這意味著年化股息為0.28美元,股息收益率為0.23%。PerkinElmer的派息率為5.24%。
PerkinElmer配置檔案
(獲取評級)
PerkinElmer,Inc.為全球診斷、生命科學和應用服務市場提供產品、服務和解決方案。它通過兩個部門運行:發現和分析解決方案以及診斷。發現與分析解決方案部門提供一整套解決方案,包括試劑、資訊學、檢測和成像技術,使科學家能夠加強生命科學研究市場的研究突破,以及合同研究和實驗室服務。
另請參閱
- 免費獲取StockNews.com關於PerkinElmer的研究報告(PKI)
- 這些機構持有達頓餐飲國際公司的股份
- 斯蒂爾凱斯的收益說明瞭他重返辦公室的原因嗎?
- 住房建設的黃金時代已經結束了嗎?
- 這三大股利支付者也擁有強勁的價格增長
- 天然氣價格繼續回升,這些股票應該會受益
想看看還有哪些對沖基金持有PKI嗎?訪問HoldingsChannel.com獲取PerkinElmer,Inc.(紐約證券交易所代碼:PKI-GET Rating)的最新13F檔案和內幕交易。
接受PerkinElmer Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對PerkinElmer和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧